<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132703">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01755078</url>
  </required_header>
  <id_info>
    <org_study_id>CPT-REN-002</org_study_id>
    <nct_id>NCT01755078</nct_id>
  </id_info>
  <brief_title>Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients</brief_title>
  <official_title>Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharma Taiwan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharma Taiwan</source>
  <oversight_info>
    <authority>China: State Administration of Traditional Chinese Medicine of the People's Republic of China</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to compare sevelamer vs. calcium-based phosphate binder in
      hemodialysis patients to achieve full-scale of medical care, including reduction of
      atherosclerotic risk factors, reduction of vascular access reconstruction rate, and
      pharmacoeconomic analysis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite end-point of Ca, P, Ca*P within K/DOQI recommendation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline, Ca, P, Ca*P</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline, lipid profile</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline, CRP</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline, iPTH (stragified)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline, homocysteine, folate and Vit B12</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CV-related event rate (OPD admission and hospitalization)</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of medical-related expenses between group</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Hemodialysis</condition>
  <condition>Hyperphosphatemia</condition>
  <condition>Cardiovascular Events</condition>
  <arm_group>
    <arm_group_label>Sevelamer HCl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium-based binder</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer HCl</intervention_name>
    <description>Non-metal phosphate binder</description>
    <arm_group_label>Sevelamer HCl</arm_group_label>
    <other_name>Renagel Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium-based phosphate binder</intervention_name>
    <arm_group_label>Calcium-based binder</arm_group_label>
    <other_name>Calcium carbonate</other_name>
    <other_name>Calcium acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged between 18-70 years old

          -  Subject with hyperphosphatemia (5.5 - 8.5 mg/dL) at both WK(-2) and WK0

          -  On stable TIW hemodialysis for 3 months or longer

        Exclusion Criteria:

          -  Patients with hypercalcemia (corrected serum calcium &gt; 10.5 mg/dL)

          -  Any of the following abnormalities: ALT or AST &gt; 3X ULN; iPTH &gt; 1000 or &lt; 150 pg/mL

          -  History of dysphagia or swallowing disorders

          -  History of GI motility disorder or GI bleeding within 3 months prior to entry
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chiu-Ching Huang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>China Medical University Hospital</affiliation>
  </overall_official>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 20, 2012</lastchanged_date>
  <firstreceived_date>December 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phosphate binder</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Sevelamer</mesh_term>
    <mesh_term>Calcium acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
